{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:42:28Z","timestamp":1763728948847,"version":"3.41.2"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Obinutuzumab was approved in China in June 2021 used in combination with chemotherapy (followed by obinutuzumab maintenance) for the treatment of adult patients with previously untreated stage II bulky, III, or IV follicular lymphoma (FL). The clinical application of obinutuzumab has recently begun in China, but there is a lack of evidence to determine under which circumstances it should be considered the treatment of choice. A comprehensive assessment is necessary to evaluate the efficacy, safety, and cost-effectiveness of obinutuzumab in adult patients with FL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To summarize the evidence on the efficacy, safety, and cost-effectiveness of obinutuzumab in adult patients with FL, aiming to provide medical professionals with evidence for informed choices in clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The approach to this evidence synthesis was a rapid review of systematic reviews\/meta-analyses (SR\/meta-analyses), health technology assessment (HTA) reports, and pharmacoeconomic studies that brings together and summarizes the efficacy, safety, and cost-effectiveness of obinutuzumab in adult patients with FL. A literature search was conducted across multiple databases, including PubMed, Embase, Wanfang, CNKI, Weipu database, the Cochrane Library, the Centre for Reviews and Dissemination (CRD) database, International Network of Agencies for Health Technology Assessment (INAHTA) and Canada\u2019s Drug Agency (CDA-AMC), International Society for Pharmacoeconomics and Outcomes Research (ISPOR), National Institute For Health and Care Excellence (NICE), Institute For Clinical And Economic Review (ICER), Grey Literature Database and Grey Net International. The studies on obinutuzumab for FL were searched in full text with <jats:italic>obinutuzumab, systematic review, meta-analysis, economics, cost, and health technology assessment<\/jats:italic> as keywords, with a search time frame from the date of database creation to 29 November 2024. The literature was screened based on predefined inclusion and exclusion criteria, and data were meticulously extracted and synthesized by two authors. Simultaneously, the quality of the literature was thoroughly assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Obinutuzumab based chemotherapy (the chemotherapy regimen-cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP); cyclophosphamide, vincristine, and prednisone (CVP); or bendamustine) significantly prolonged progression free survival (PFS) compared to other chemotherapy regimen at primary and updated analyses. The incidence of grade 3\u20135 AEs, infusion-related reactions (IRRs), and infection were higher in the obinutuzumab based chemotherapy group compared to other chemotherapies. The economic researches conducted in China, United States, Japan, Italy and Norway had demonstrated that obinutuzumab-based chemothrepy was cost-effective compared to other chemothrepies. Although obinutuzumab significantly prolonged PFS and was cost-effective, its safety profile was considered lower.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Compared with other chemothrapy regimen, obinutuzumab based chemotherapy significantly prolonged PFS and was cost-effective, while its safety profile was considered lower. Therefore, medical professionals should be caution when using or introducing obinutuzumab treatment for FL patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1426772","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T05:10:25Z","timestamp":1735881025000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy, safety and cost-effectiveness of obinutuzumab in patients with follicular lymphoma: a rapid review"],"prefix":"10.3389","volume":"15","author":[{"given":"Chao","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunzhuo","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Men","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruixia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yishan","family":"Bu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinpeng","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huier","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/hon.2828","article-title":"Obinutuzumab-related adverse events: a systematic review and meta-analysis","volume":"39","author":"Amitai","year":"2021","journal-title":"Hematol. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1089\/108497801300189245","article-title":"Evaluation on a six-dose treatment of anti CD 20 monoclonal antibody in patients with refractory follicular lymphoma","volume":"16","author":"Avil\u00e9s","year":"2001","journal-title":"Cancer biotherapy and Radiopharm."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1182\/blood.2021013526","article-title":"Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study","volume":"139","author":"Bachy","year":"2022","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2147\/CEOR.S317885","article-title":"Obinutuzumab plus chemotherapy compared with rituximab plus chemotherapy in previously untreated Italian patients with advanced follicular lymphoma at intermediate-high risk: a cost-effectiveness analysis","volume":"13","author":"Bellone","year":"2021","journal-title":"Clin. Outcomes Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1007\/s00277-023-05306-2","article-title":"Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma-a real-world multicenter retrospective cohort study","volume":"102","author":"Berger","year":"2023","journal-title":"Ann. Hematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/1747-0080.12754","article-title":"Effectiveness of dietary interventions in mental health treatment: a rapid review of reviews","volume":"79","author":"Burrows","year":"2022","journal-title":"Nutr. and dietetics J. Dietitians Assoc. Aust."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall survival benefit in patients with rituximab-refractory indolent non-hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study","volume":"36","author":"Cheson","year":"2018","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3760\/cma.j.issn.0253-2727.2020.07.002","article-title":"Chinese anti-cancer association, and Chinese society of hematology, Chinese medical association","volume":"41","year":"2020","journal-title":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue Zazhi."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/cncr.35137","article-title":"Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: a systematic review and network meta-analysis of randomized trials","volume":"130","author":"Chu","year":"2024","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s00432-022-04155-2","article-title":"Comparative analysis of rituximab or obinutuzumab combined with CHOP in first-line treatment of follicular lymphoma","volume":"149","author":"Claustre","year":"2023","journal-title":"J. cancer Res. Clin. Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.2217\/fon-2022-0112","article-title":"Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review","volume":"18","author":"Davies","year":"2022","journal-title":"Future Oncol. Lond. Engl."},{"key":"B12","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"2021","journal-title":"Ann. Oncol. official J. Eur. Soc. Med. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"999","DOI":"10.3390\/cancers15040999","article-title":"Body composition in patients with follicular lymphoma: asso-ciations between changes in radiomic parameters in patients treated with R-CHOP-like and R-B regimens: LyRa 01F","volume":"15","author":"Esposito","year":"2023","journal-title":"Cancers (Basel)"},{"unstructured":"GAZYVA\u00ae(obinutuzumab) injection, for intravenous infusion\n          \n          \n          2016","key":"B14"},{"key":"B15","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s12185-022-03363-3","article-title":"Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group","volume":"115","author":"Fujiwara","year":"2022","journal-title":"Int. J. Hematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e807","DOI":"10.1097\/HS9.0000000000000807","article-title":"Efficacy and safety of obinutuzumab-chemotherapy combinations in front-line treatment of follicular non-hodgkin lymphoma during the COVID-19 pandemic: a study of krohem, the Croatian cooperative group for hematologic diseases","volume":"6","author":"Galusic","year":"2022","journal-title":"Hemasphere"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e076335","DOI":"10.1136\/bmj-2023-076335","article-title":"Updated recommendations for the Cochrane rapid review methods guidance for rapid reviews of effectiveness","volume":"384","author":"Garritty","year":"2024","journal-title":"BMJ Clin. Res. ed."},{"key":"B18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3324\/haematol.2016.152272","article-title":"Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma","volume":"102","author":"Grigg","year":"2017","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/jebm.12594","article-title":"Rapid review: a review of methods and recommendations based on current evidence","volume":"17","author":"Guo","year":"2024","journal-title":"J. evidence-based Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1080\/13696998.2018.1489254","article-title":"Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US","volume":"21","author":"Guzauskas","year":"2018","journal-title":"J. Med. Econ."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1080\/10428194.2018.1551532","article-title":"Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States","volume":"60","author":"Guzauskas","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"B22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12961-016-0155-7","article-title":"What are the best methodologies for rapid reviews of the research evidence for evidence-informed decision making in health policy and practice: a rapid review","volume":"14","author":"Haby","year":"2016","journal-title":"Health Res. policy Syst."},{"key":"B23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40258-018-0401-y","article-title":"Cost-effectiveness of obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance versus bendamustine alone in treatment of patients with rituximab-refractory follicular lymphoma in Norway","volume":"16","author":"Haukaas","year":"2018","journal-title":"Appl. Health Econ. Health Policy"},{"unstructured":"Gazyvaro\u00aein combination with bendamustine for the treatment of relapsed\/refractory follicular lymphoma (FL)\n          \n          \n          2016","key":"B24"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"unstructured":"INAHTA checklist\n          \n          \n          2014","key":"B26"},{"key":"B27","first-page":"001370","article-title":"The efficacy and safety of Obinutuzumab in the treatment of follicular lymphoma","volume-title":"A meta-analysis","author":"Leng","year":"2023"},{"key":"B28","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3760\/cma.j.cn115356-20210928-00230","article-title":"Chinese expert consensus on principles for clinical use of obinutuzumab","volume":"30","author":"Ma","year":"2021","journal-title":"J. Leukemia and Lymphoma"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e230073","DOI":"10.57264\/cer-2023-0073","article-title":"Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma","volume":"12","author":"Ma","year":"2023","journal-title":"J. Comp. Eff. Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/bjh.16872","article-title":"The investigation and management of follicular lymphoma","volume":"191","author":"McNamara","year":"2020","journal-title":"Br. J. Haematol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"69","DOI":"10.4274\/tjh.galenos.2024.2024.0015","article-title":"Advancements in the management of follicular lymphoma: a comprehensive review","volume":"30","author":"Merryman","year":"2024","journal-title":"Turk J. Haematol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41408-021-00539-8","article-title":"Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed\/refractory follicular lymphoma: final analysis of a Phase Ib\/II trial","volume":"11","author":"Morschhauser","year":"2021","journal-title":"Blood Cancer J."},{"unstructured":"Cost-effectiveness of obinutuzumab (Gazyvaro\u00ae) for the first line treatment of follicular\n          \n          \n          2018","key":"B34"},{"unstructured":"Obinutuzumab for untreated advanced follicular lymphoma\n          \n          \n          2018","key":"B35"},{"unstructured":"Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab\n          \n          \n          2020","key":"B36"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1080\/13696998.2020.1791890","article-title":"Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients","volume":"23","author":"Ohno","year":"2020","journal-title":"J. Med. Econ."},{"key":"B38","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.2217\/fon-2019-0193","article-title":"The role of obinutuzumab in the management of follicular lymphoma","volume":"15","author":"O'Nions","year":"2019","journal-title":"Future Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1016\/j.clml.2021.12.010","article-title":"Combination of atezolizumab and obinutuzumab in patients with relapsed\/refractory follicular lymphoma and diffuse large B-cell lymphoma: results from a phase 1b study","volume":"22","author":"Palomba","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"unstructured":"pCODR final clinical guidance report - obinutuzumab (gazyva) for follicular lymphoma\n          \n          \n          2017","key":"B40"},{"unstructured":"pCODR final clinical guidance report - obinutuzumab (gazyva) for follicular lymphoma\n          \n          \n          2018","key":"B41"},{"volume-title":"Obinutuzumab, solution for I.V. infusion 1000 mg in 40 mL, Gazyva\u00ae","year":"2016","article-title":"PBAC policy summary document","key":"B42"},{"key":"B43","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1177\/1078155215603230","article-title":"Randomized controlled trials in relapsed\/refractory follicular lymphoma: a systematic review and meta-analysis","volume":"22","author":"Police","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"unstructured":"obinutuzumab, 1,000mg, concentrate for solution for infusion (Gazyvaro\u00ae)\n          \n          \n          2018","key":"B44"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","article-title":"Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial","volume":"17","author":"Sehn","year":"2016","journal-title":"Lancet. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1200\/JCO.2014.59.2139","article-title":"Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-hodgkin lymphoma: final analysis of the GAUSS study","volume":"33","author":"Sehn","year":"2015","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"B48","doi-asserted-by":"publisher","first-page":"615","DOI":"10.18553\/jmcp.2021.20424","article-title":"Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma","volume":"27","author":"Spencer","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e046187","DOI":"10.1136\/bmjopen-2020-046187","article-title":"What are the consequences of caring for older people and what interventions are effective for supporting unpaid carers? A rapid review of systematic reviews","volume":"11","author":"Spiers","year":"2021","journal-title":"BMJ open"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e19536","DOI":"10.1200\/jco.2021.39.15_suppl.e19536","article-title":"Healthcare utilization and costs associated with first-line treatment with obinutuzumab- and rituximab-based regimens for follicular lymphoma","volume":"39","author":"Ta","year":"2021","journal-title":"JCO"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e919","DOI":"10.1097\/HS9.0000000000000919","article-title":"Obinutuzumab versus rituximab immunochemotherapy in previously untreated iNHL: final results from the GALLIUM study","volume":"7","author":"Townsend","year":"2023","journal-title":"HemaSphere"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00598-x","article-title":"Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials","volume":"12","author":"Wang","year":"2022","journal-title":"Blood Cancer J."},{"key":"B53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.14055\/j.cnki.33-1056\/f.2022.11.022","article-title":"Economic Evaluation of obinutuzumab in combination with chemotherapy for primary treatment of follicular lymphoma-comparison with rituximab in combination with chemotherapy","volume":"39","author":"Wei","year":"2022","journal-title":"Health Econ. Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"5659","DOI":"10.1182\/bloodadvances.2021006131","article-title":"Safety and efficacy of atezolizumab with obinutuzumab and bendamustine in previously untreated follicular lymphoma","volume":"6","author":"Younes","year":"2022","journal-title":"Blood Adv."},{"key":"B55","doi-asserted-by":"publisher","first-page":"289","DOI":"10.21147\/j.issn.1000-9604.2021.03.01","article-title":"Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)","volume":"33","author":"Zhu","year":"2021","journal-title":"Chin. J. Cancer Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1200\/JCO.23.00775","article-title":"ROSEWOOD: a phase II randomized study of zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy in patients with relapsed or refractory follicular lymphoma","volume":"41","author":"Zinzani","year":"2023","journal-title":"J. Clin. Oncol. official J. Am. Soc. Clin. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1426772\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T05:10:35Z","timestamp":1735881035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1426772\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":56,"alternative-id":["10.3389\/fphar.2024.1426772"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1426772","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"article-number":"1426772"}}